Vanda Pharmaceuticals Files 8-K for Regulation FD Disclosure
Ticker: VNDA · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: VNDA
TL;DR
Vanda Pharma filed an 8-K on March 17th for a March 14th Reg FD disclosure.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on March 17, 2025, reporting an event on March 14, 2025. The filing pertains to a Regulation FD Disclosure and includes information about the company's common stock and Series A Junior Participating Preferred Stock Purchase Rights.
Why It Matters
This filing indicates a disclosure event under Regulation FD, which ensures that material information is disseminated to the public in a fair and timely manner.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, which is routine corporate communication.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- March 17, 2025 (date) — Filing Date
- March 14, 2025 (date) — Earliest Event Date
- Regulation FD (regulation) — Disclosure Type
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to provide a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 14, 2025.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 17, 2025.
What type of stock rights are mentioned in the filing?
The filing mentions Series A Junior Participating Preferred Stock Purchase Rights.
What is the principal executive office address of Vanda Pharmaceuticals Inc.?
The principal executive office address is 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding Vanda Pharmaceuticals Inc. (VNDA).